- Email: [email protected]
Translational advances in urologic cancer
Urologic Oncology: Seminars and Original Investigations 25 (2007) 412
Seminar section introduction II
Translational advances in urologic cancer The ultimate goal of discovery in cancer is to generate knowledge that can be exploited to treat the disease more effectively. The past few years have seen a dramatic application of this paradigm in the field of kidney cancer. The discovery of the Von Hippel Lindau disease gene by Drs. Marston Linehan, Berton Zbar, and colleagues at the NCI led rapidly to a fundamental understanding of the biological basis of sporadic kidney cancer. These studies uncovered the central role of hypoxia in stimulating new blood vessel formation in this disease. These advances have now been translated into multiple effective therapies for this disease, which are rapidly transforming the management of this disease. Dr. Robert Uzzo from Fox Chase Cancer Center provided the Society of Urologic Oncology (SUO) with a superb lecture covering these advances and their role in the management of kidney cancer. Although our depth of knowledge of prostate and bladder cancer has arguably not
1078-1439/07/$ – see front matter © 2007 Elsevier Inc. All rights reserved. doi:10.1016/j.urolonc.2007.07.009
yet reached the level of understanding achieved in renal cancer, major advances in the study of these tumors, many of which were presented at the SUO meeting, have led to the initiation of multiple preclinical and clinical studies of targeted therapies in these diseases as well. Drs. Martin Gleave and Colin Dinney, of the University of British Columbia and M.D. Anderson Cancer Center, respectively, provided illuminating talks covering many of these studies. All three surgeon-scientists have provided summaries of their SUO talks for publication in this issue of Urologic Oncology. We thank them for their efforts. Robert E. Reiter, M.D., M.B.A. Department of Urology Jonsson Comprehensive Cancer Center David Geffen School of Medicine at UCLA Los Angeles, CA, USA
Seminar section introduction II
Translational advances in urologic cancer The ultimate goal of discovery in cancer is to generate knowledge that can be exploited to treat the disease more effectively. The past few years have seen a dramatic application of this paradigm in the field of kidney cancer. The discovery of the Von Hippel Lindau disease gene by Drs. Marston Linehan, Berton Zbar, and colleagues at the NCI led rapidly to a fundamental understanding of the biological basis of sporadic kidney cancer. These studies uncovered the central role of hypoxia in stimulating new blood vessel formation in this disease. These advances have now been translated into multiple effective therapies for this disease, which are rapidly transforming the management of this disease. Dr. Robert Uzzo from Fox Chase Cancer Center provided the Society of Urologic Oncology (SUO) with a superb lecture covering these advances and their role in the management of kidney cancer. Although our depth of knowledge of prostate and bladder cancer has arguably not
1078-1439/07/$ – see front matter © 2007 Elsevier Inc. All rights reserved. doi:10.1016/j.urolonc.2007.07.009
yet reached the level of understanding achieved in renal cancer, major advances in the study of these tumors, many of which were presented at the SUO meeting, have led to the initiation of multiple preclinical and clinical studies of targeted therapies in these diseases as well. Drs. Martin Gleave and Colin Dinney, of the University of British Columbia and M.D. Anderson Cancer Center, respectively, provided illuminating talks covering many of these studies. All three surgeon-scientists have provided summaries of their SUO talks for publication in this issue of Urologic Oncology. We thank them for their efforts. Robert E. Reiter, M.D., M.B.A. Department of Urology Jonsson Comprehensive Cancer Center David Geffen School of Medicine at UCLA Los Angeles, CA, USA